WASHINGTON — The government shutdown could soon jeopardize highly anticipated new drugs from Janssen, Sanofi (SNY), and Novartis (NVS) for depression, diabetes and multiple sclerosis, as well as a host of other potential new therapies, according to a STAT analysis of upcoming regulatory decision dates.

President Trump has warned that the shutdown — already the longest in history — could stretch on for “months or even years.” And though the Food and Drug Administration can retain more than half of its workforce thanks to application fees paid by drug and device makers, Commissioner Scott Gottlieb has cautioned the agency only has about three more weeks’ worth of funding to draw down. The agency can’t accept any new fees during the shutdown.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • How to deal with an anticipated crunch: FDA decision on any application gets extended by the duration of the government shut-down (equal burden-share). Thus no preferential treatment, no over-worked FDA staff – just equal delay.
    How to deal with a government shut-down : chose a wiser President next time. And force legislation that mandates continued pay to all government employees. They should NOT bare the burden of one man’s decisions !!!

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy